Metabolomics Reveals Potential Biomarkers for Early Detection of irAEs in ICI-Treated Patients
Introduction In recent years, cancer immunotherapy, particularly ICIs, has achieved significant advancements in the clinical treatment of malignancies.1 ICIs, which include cytotoxic T-lymphocyte-associated antigen 4 inhibitors, programmed cell death …